MedPath

PROTHENA BIOSCIENCES LIMITED

๐Ÿ‡ช๐Ÿ‡ธSpain
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

19

Active:11
Completed:5

Trial Phases

2 Phases

Phase 1:16
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (18 trials with phase data)โ€ข Click on a phase to view related trials

Phase 1
16 (88.9%)
Phase 3
2 (11.1%)

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Phase 1
Terminated
Conditions
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Interventions
First Posted Date
2017-11-08
Last Posted Date
2020-08-20
Lead Sponsor
Prothena Biosciences Limited
Target Recruit Count
21
Registration Number
NCT03336580
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Tufts Medical Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic Minnesota, Rochester, Minnesota, United States

๐Ÿ‡บ๐Ÿ‡ธ

Oregon Health and Science University, Portland, Oregon, United States

and more 4 locations

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Phase 1
Completed
Conditions
Psoriasis
Interventions
Other: Placebo
First Posted Date
2015-12-15
Last Posted Date
2018-05-04
Lead Sponsor
Prothena Biosciences Limited
Target Recruit Count
48
Registration Number
NCT02630901
Locations
๐Ÿ‡บ๐Ÿ‡ธ

TCR Medical Corporation, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Universal Medical and Research Center, LLC, Coral Gables, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Renstar Medical Research, Ocala, Florida, United States

and more 6 locations

Single Ascending Dose Study of PRX003 in Healthy Subjects

Phase 1
Completed
Conditions
Psoriasis
Interventions
Other: Placebo
First Posted Date
2015-06-01
Last Posted Date
2016-03-16
Lead Sponsor
Prothena Biosciences Limited
Target Recruit Count
40
Registration Number
NCT02458677
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Other: Placebo
First Posted Date
2014-06-06
Last Posted Date
2016-10-21
Lead Sponsor
Prothena Biosciences Limited
Target Recruit Count
64
Registration Number
NCT02157714
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Collaborative Neuroscience Network, LLC, Long Beach, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

๐Ÿ‡บ๐Ÿ‡ธ

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

and more 5 locations

Single Ascending Dose Study of PRX002 in Healthy Subjects

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Other: Placebo
First Posted Date
2014-03-24
Last Posted Date
2015-02-10
Lead Sponsor
Prothena Biosciences Limited
Target Recruit Count
40
Registration Number
NCT02095171

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.